Neuropace Inc (NPCE)
NeuroPace, Inc. is a U.S.-based medical device company focused on treatments for drug-resistant focal epilepsy. Its core offering is the RNS System, a brain-responsive neuromodulation platform designed to deliver personalized, real-time therapy at the seizure source. The system includes the RNS neurostimulator, cortical strip and depth leads, a Patient Remote Monitor, and related implantable and non-implantable accessories. The company also provides a physician tablet for device programming and patient management, a secure patient data management system, and the nSight Platform, which generates patient reports and programming guidance for clinicians. NeuroPace sells its products to hospital facilities for both initial implant procedures and replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NPCE
|
$8.03
|
-45.4% Downside
|
Overvalued
|
$20
|
36.0% Upside
|
Undervalued
|
Good
|
0.0%
|
November 10, 2026
|
42.0x
|
4.7x
|
504.9 M
|
517.3 M
|
12.3%
|
74.2%
|
-3.1
|
71.8%
|
